Trial Profile

A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-Daily

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Islatravir (Primary) ; Ulonivirine (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide
Indications HIV-1 infections
Focus Adverse reactions
Acronyms IMAGINE-DR; MK-8591-013
Sponsors Merck Sharp & Dohme Corp.

12 Feb 2025 Status changed from active, no longer recruiting to completed.
09 Jan 2025 Planned End Date changed from 31 Mar 2025 to 31 Jan 2025.
09 Jan 2025 Planned primary completion date changed from 31 Mar 2025 to 31 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com